Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Immunodeficiency by defective expression of HLA class 2 is a rare primary genetic immunodeficiency disorder characterized by partial or complete absence of human leukocyte antigen class 2 expression resulting in severe defect in both cellular and humoral immune response to antigens. The disorder presents clinically as marked susceptibility to infections, severe malabsorption and failure to thrive and is often fatal in early childhood.
Biomarker and diagnostic research for MHC class II deficiency has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for MHC class II deficiency.
63 publications have been identified in PubMed for MHC class II deficiency. Research spans Basic Science / Preclinical (64%), Case Report / Case Series (16%), and Review / Meta-Analysis (5%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 39 | 64% |
Patient case studies | 10 | 16% |
Research summaries | 3 | 5% |
New treatment approaches | 3 | 5% |
Testing and diagnosis research | 2 | 3% |
Clinical study results | 2 | 3% |
Disease patterns and progression | 2 | 3% |
Liu X (2026). [PMID: 41789066](https://pubmed.ncbi.nlm.nih.gov/41789066/). *Front Immunol*. [Basic Science / Preclinical]
Zhu Z (2026). [PMID: 42161938](https://pubmed.ncbi.nlm.nih.gov/42161938/). *Nat Commun*. [Basic Science / Preclinical]
Liu R (2026). [PMID: 41796697](https://pubmed.ncbi.nlm.nih.gov/41796697/). *Fish Shellfish Immunol*. [Basic Science / Preclinical]
Li X (2026). [PMID: 41984049](https://pubmed.ncbi.nlm.nih.gov/41984049/). *FASEB J*. [Basic Science / Preclinical]
Nuñez-Nuñez ME (2026). [PMID: 41558066](https://pubmed.ncbi.nlm.nih.gov/41558066/). *Hum Immunol*. [Case Report / Case Series]
Kawarizadeh K (2026). [PMID: 42231978](https://pubmed.ncbi.nlm.nih.gov/42231978/). *iScience*. [Basic Science / Preclinical]
Liu H (2026). [PMID: 42174699](https://pubmed.ncbi.nlm.nih.gov/42174699/). *Chin Med*. [Basic Science / Preclinical]
Dias BRS (2026). [PMID: 41676550](https://pubmed.ncbi.nlm.nih.gov/41676550/). *bioRxiv*. [Basic Science / Preclinical]
Zhang X (2026). [PMID: 41372415](https://pubmed.ncbi.nlm.nih.gov/41372415/). *Nature*. [Basic Science / Preclinical]
Kim SI (2026). [PMID: 41025699](https://pubmed.ncbi.nlm.nih.gov/41025699/). *Cancer Immunol Res*. [Gene Therapy / Novel Therapeutics]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about MHC class II deficiency